Overview

Study of Irofulven in Combination With Oxaliplatin in Patients With Advanced Solid Tumors

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) and to investigate the efficacy, safety and pharmacokinetics of irofulven combined with oxaliplatin in patients with advanced solid tumors.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Eisai Inc.
Treatments:
Irofulven
Oxaliplatin